Brief: Sab Biotherapeutics Announces Sab-176 Met Its Primary Endpoint In Phase 2A Challenge Study In Adults Infected With Influenza Virus

SAB Biotherapeutics

01/12/2021 12:34

Dec 1 (Reuters) - SAB Biotherapeutics Inc  SABS.O :
    * SAB BIOTHERAPEUTICS ANNOUNCES SAB-176 MET ITS PRIMARY
ENDPOINT
IN PHASE 2A CHALLENGE STUDY IN ADULTS INFECTED WITH INFLUENZA
VIRUS
    * SAB BIOTHERAPEUTICS INC - TOPLINE DATA SHOW SAB-176
ACHIEVED
STATISTICALLY SIGNIFICANT REDUCTIONS IN VIRAL LOAD AND CLINICAL
SYMPTOMS
    * SAB BIOTHERAPEUTICS INC - SAB PLANS TO FURTHER EVALUATE
SAB-176
IN A PHASE 2 INFLUENZA CLINICAL TRIAL SLATED TO BEGIN IN 2Q 2022
    * SAB BIOTHERAPEUTICS INC -  TOPLINE DATA SHOW SAB-176 SAFE
AND
WELL-TOLERATED

Source text for Eikon:  ID:nGNX8c7dgM 
Further company coverage:  SABS.O 

 ((Reuters.Briefs@thomsonreuters.com;))